Zafgen Says Obesity Drug Spurs Weight Loss in Mid-Stage Study
This article is for subscribers only.
Zafgen Inc., a closely held developer of an experimental drug for obesity, said its therapy yielded weight loss of as much as 10 kilograms (22 pounds) in three months, an early look at study results showed.
Patients taking the drug, called beloranib, also showed lower levels of triglycerides and low-density lipoprotein, or LDL, cholesterol, and felt less hunger after 12 weeks, the Cambridge, Massachusetts-based company said today in a statement. The data on the first 19 patients to complete the 148-person study were presented today at the American Diabetes Association meeting in Chicago.